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The Management of Cervical Intra-epithelial 
Neoplasia (CIN): Extensiveness and Costs in The 
Netherlands 
M. van Ballegooijen, M.A. Koopmanschap and J.D.F. Habbema 
In order to provide greater insight into both the extensiveness and the medical costs of the diagnosis and treatment 
of screen-detected cervical intra-epithelial neoplasia (CIN) in general medical practice in The Netherlands, data 
from national registries and gynaecology departments were retrieved, and experts were interviewed. Of the 5060 
women diagnosed with CIN in 1988, more than 50% were treated in hospital with conisation or hysterectomy, 
which on average took 5.5 days stay per admission. The assessed average duration of the total pre- and post- 
treatment period is 4.6 years. The average total medical costs in women with detected CIN III are Dfl3700 per 
woman. The diagnosis of CIN I and II involves more medical procedures and time than CIN III, but fewer women 
have conisation or hysterectomy, resulting in lower total medical costs (Dfl2572). The overall extent and costs of 
the management of CIN should be accounted for when balancing the benefits, unfavourable effects and costs of 
cervical cancer screening. 
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INTRODUCTION 
THE AIM of this study was to provide greater insight into the 
extent and the medical costs of the diagnosis and treatment 
of screen-detected cervical intra-epithelial neoplasia (CIN) in 
general medical practice. Such knowledge is most important 
for assessing the balance between costs and favourable and 
unfavourable ffects of screening for cervical cancer. Part of the 
unfavourable ffects is caused by detection of non-progressive 
lesions. The number of women involved is increasing because 
the cut-off point in cytology for colposcopic follow-up has been 
shifting to lower grade abnormalities. 
It is often stressed that the management of CIN is quick, safe 
and cheap. Even if this were true in an ideal situation, such 
a statement should be verified for general medical practice. 
Available literature refers to data from one or two selected 
treatment centres per study [l-3]. We studied the number of the 
various diagnostic and treatment procedures from national data, 
and when this was not possible, from a number of gynaecological 
departments covering 25% of the population. Data from the 
Dutch national hospital admission registration (coverage over 
99%) were combined with centrally collected data from at least 
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85% of the cytopathology laboratories (PALGA, Pathological 
National Automated Archive, The Netherlands). Currently, 
The Netherlands is one of the few countries for which these data 
are available on a national scale. 
MATERIALS AND METHODS 
The study concerns women with histologically confirmed 
CIN: the episode studied starts with the first visit to the 
gynaecology department for follow-up after an abnormal Pap 
smear and ends after the woman is referred back to normal 
screening practice. The situation for women having invasive 
cervical cancer has been considered elsewhere [4]. This study 
concentrates on pre-invasive disease, cervical intra-epithelial 
neoplasia: CIN I/II and III. 
The annual number of women in whom CIN I, II and III has 
been diagnosed in The Netherlands was retrieved from PALGA, 
which is connected to the cytopathology laboratories. All women 
with histologically confirmed CIN in the period 1987-1990 were 
selected [S]. For each of these women, the maximal diagnosis 
within this period was established. The population coverage rate 
of PALGA was 70%, 85%, 98% and 99.6% in 1987,1988, 1989 
and 1990, respectively. The annual total numbers (corrected for 
incomplete coverage) of women detected with CIN I/II and CIN 
III for 1988 were 2590 and 2570, respectively, and for 1990, 
3410 and 3420, respectively. 
The annual number of conisations (2180), hysterectomies 
(425) and days of hospitalisation (15 780) associated with the 
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diagnosis and treatment of CIN (see Table l), were retrieved 
from national data on hospital admissions, selecting admissions 
with dysplasia or carcinoma in situ of the cervix uteri (ICD-9 
codes 622.1 and 233.1, respectively) as the main diagnosis [6]. 
Some of the cases with hy:sterectomy also had a secondary 
diagnosis, but there were alw hysterectomy cases with dysplasia 
or carcinoma in situ in the sec:ondary diagnoses, which were not 
included in our figures. Together with the retrieved annual 
number of women with CD?, the hospital data enabled us to 
compute an average number of medical procedures per woman 
with CIN (Table 1). 
In the search for CIN grade-specific data and data on out- 
patient procedures (particularly conservative treatments), all 
gynaecology departments inThe Netherlands were sent a request 
for annual figures on diagnostic and treatment procedures in the 
management of CIN. Gynaecologists from 10% of the hospitals 
responded with relevant data, mostly by sending annual reports, 
data on treatment of women with CIN III (there are hardly any 
data on CIN I and II), annual number of conisations, conserving 
treatments and colposcopies, covering the period 1984-1989. 
These hospitals cover 25% [7] of the Dutch population. In these 
data, 33% of the women with CIN III had conservative treatment 
(cryocoagulation, laser evaporation and hot loop diathermy are 
widely used in The Netherlands), 56% had conisation and 11% 
hysterectomy. These fractions were accepted as our estimates. 
In the 50% of responding hospitals with the highest frequency 
of conservative treatment, these percentages summated to 58%, 
35% and 7%, respectively. In addition, we assumed that 15% of 
all women treated will need retreatment at least once [8], 75% of 
whom will receive conservative treatment and 25% of whom will 
receive conisation, amounting to 0.44 (0.33 + 0.75 X 0.15) 
conservative treatments and 0.60 (0.56 + 0.25 X 0.15) conisa- 
tions. 
In the next step, the fraction of conisations was multiplied by 
the total number of women diagnosed with CIN III, resulting in 
the number of conisations which should be attributed to women 
with CIN III (0.60 X 2570 = 1542). The number of conisations 
which should be attributed to women with CIN I or II was 
calculated by subtraction (2180 - 1542 = 638), and the fraction 
of women with CIN I or II having conisation was determined 
(638/2590 =0.25). The same procedurewas followed tocalculate 
the number of hysterectomies and conservative treatments in 
women with CIN I/II. The total annual number of conservative 
treatments was calculated from the ratio between conservative 
treatments and conisations in the reporting gynaecology depart- 
ments and the total annual number of conisations (1.273 x 2180 
= 2775). The fraction-for which no data were available-of 
women with CIN I/II without conservative treatment, conis- 
ation, or hysterectomy was calculated as the residue after 
subtracting the total fraction of treatment procedures from 1 
plus the fraction of retreatments (1.15-0.63-0.25-0.05, see 
Table 1). The annual number of colposcopies reported from the 
gynaecology departments was extrapolated to the national level 
(15 466 colposcopies). 
Table 1. Estimated average number of diagnostic and treatment procedures, and days in hospital in women 
with screen-detected CIN 
CIN I/II CIN III All CIN 
Number per Number per Annual 
woman woman members 
a b C 
Treatment procedures 
No treatment 
Conservative treatment 
Conisation 
Hysterectomy 
Hospital days* 
Conisation 
Hysterectomy 
Other 
Total 
Hospital admissions 
Conisation 
Hysterectomy 
Other 
Total 
Assessment procedures 
Pap smears 
Colposcopy 
Biopsy 
Number of consultations and duration of total period studied 
Consultation:; 
Years 
0.21 0.00 544 
0.63 0.44 2775 
0.25 0.60 2180 
0.05 0.11 425 
1.1 2.7 9810 
0.7 1.3 5100 
0.1 0.2 870 
1.9 4.3 15 780 
0.25 0.60 2180 
0.05 0.11 425 
0.03 0.08 285 
0.33 0.79 2890 
8.7 7.3 41383 
6.0 4.6 27 200 
2.4 1.8 10799 
9.0 7.6 42 680 
4.9 4.3 23851 
c = a x 2590 i- b x 2570, in which 2590 and 2570 are the annual number of women with CIN I/II and CIN III, 
respectively. *Example: 1.1 days for conisations per woman with CIN I/II = 0.25 conisations x 4.5 days (Table 2). 
Women were diagnosed in 1988. 
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To collect information on aspects for which no detailed 
large scale data were available-number of consultations at the 
gynaecology department, Pap smears, colposcopies and (ecto- 
or endocervical) biopsies, and the duration of the total period 
studied-four gynaecologist-colposcopists from different hospi- 
tals (three university hospitals and one regional hospital) were 
interviewed in a standardised way. From these interviews, we 
could assess which aspects show variation in practice, and 
consequently, since large scale data are missing, remain uncer- 
tain. The possible influences of these uncertainties were studied 
in a sensitivity analysis. 
A cost-effectiveness analysis was the goal of the cost part of 
this study and the costs were assessed from the viewpoint of 
society. An analysis of the true resource costs of all relevant 
procedures was, however, beyond the scope of this study. Apart 
from the cost per colposcopy and per hospital day, which reflect 
an assessment of the true resource costs, the costs of diagnosis 
and treatment have been approximated by tariffs charged (1993) 
in The Netherlands (Table 2). The cost per colposcopy was 
assessed by interviewing colposcopists for time investment, by 
reviewing financial accounts of gynaecology departments, and 
by cost analysis of the equipment. The cost per hospital day is 
an estimate of the average cost per day (weighted average for the 
general and teaching hospitals, and of general and intensive 
care), including “hotel” costs, nursing and medical staff, stan- 
dard medical equipment, medication and overhead costs. We 
performed a sensitivity analysis on a lower cost per hospital day 
(see Discussion). The costs are presented in Dutch guilders (Dfl) 
in Table 3. In 1993, the exchange rate for the British pound 
sterling was Df12.8 and for the U.S. dollar Dfll.85. 
RESULTS 
The resulting numbers of treatments and days of hospitalis- 
ation are summarked in Table 1. As expected, the fraction of 
women treated with hysterectomy or conisation was much lower 
in CIN I/II than in CIN III. Important differences in practice 
occurred in the management of low grade lesions. The gynaecolo- 
gists interviewed confirmed that in some of the gynaecology 
departments in The Netherlands, women with CIN I and, to a 
lesser extent, CIN II were treated only if there was persistence 
or progression in the first 2 years after diagnosis. In our 
calculation, the fraction of women with diagnosed CIN I/II who 
have no treatment was 2 1%. Assuming that half the women with 
CIN I/II show regression within 2 years, this would mean that 
approximately 40% of the women diagnosed with this condition 
were initially followed-up with cytology and colposcopy only. In 
a sensitivity analysis, we examined the effect of all women with 
CIN I/II being treated immediately after diagnosis, other than 
by conisation or hysterectomy. We also examined the effect of 
all these women being initially followed up with cytology and 
colposcopy (Table 4). 
The required numbers of Pap smears, colposcopies, and 
biopsies per women reported by the colposcopists interviewed 
showed little variation with primary diagnosis. We assumed 1 
Pap smear, 1.2 colposcopies and 1.4 biopsies per women during 
1.2 consultations over a period of 0.3 years. In women initially 
followed up with cytology and colposcopy only, but treated 
eventually (in our calculations 21% of the women with CIN I/ 
II), these numbers were doubled because a second diagnosis is 
required. In treated women, the numbers were increased by 30% 
for (suspected) recurrence. During follow-up without treatment, 
one colposcopy and Pap smear per 6 months was added. 
Finally, for all women with CIN, we accounted for consul- 
tations, Pap smears and colposcopies during the follow-up after 
primary management. This follow-up ends when a woman is 
referred for routine screening. The different kinds of schedules 
used in this period are: 
- 5 years of follow-up with both 
cytology and colposcopy; 
- 5 years of follow-up with only 
cytology; 
- 3 years of colposcopy followed by 
2 years of cytology; 
eight consultations in 
total 
- 1 year with one colposcopic and two two consultations in 
cytologic evaluations total. 
We basically assumed an intermediate schedule with six consul- 
tations, six Pap smears, three colposcopies and a duration of 4 
years. In a sensitivity analysis we accounted for more and 
less intensive schedules (Table 4). The resulting numbers of 
diagnostic procedures during the total period studied are shown 
in Table 1. 
Table 2 presents the cost per procedure. In Table 3, the 
estimated costs for diagnosis and treatment of CIN are presented. 
The costs of the medical procedures were approximately Dfl 
1600 for all grades of CIN. The total costs in CIN III were 45% 
higher than in CIN I/II, due to the larger number of hospital 
days. The costs of hospitalisation accounted for more than half 
of the total costs of Df13727 of the diagnosis, treatment and after 
treatment follow-up per woman with CIN III. 
DISCUSSION 
Multiplication of the estimated numbers of colposcopies per 
women with the estimated annual number of cases results in the 
Table 2. Costs (in Dutch guilders) per medicalprocedure in & manugemmt of CIN 
Cost per procedure Days in hospital Total costs* 
Visit 
Pap smear 
Primary colposcopy 
Secondary colposcopy 
Biopsy 
Cryocoagulation etc. 
Conisation 
Hysterectomy 
67 0 67 
52 0 52 
145 0 145 
106 0 106 
87 0 87 
123 0 123 
401-t 4.5 2622 
2536t 12 8458 
*Cost per procedure plus Df1494 per day in hospital; t Including Dfl 165 for presurgery laboratory procedures and chest 
X-ray. 
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Table 3. Estimated average medical costs (in Dutch guikfers) per woman with screen-detected CZN 
CIN I/II CIN III 
Consultation* 201 7.8% 201 5.4% 
Pap smear 454 17.7% 380 10.2% 
ColposcoPYt 673 26.2% 522 14.0% 
Biopsy 206 8.0% 158 4.2% 
Conservative treatment 78 3.0% 54 1.4% 
Conisation 646 25.1% 1573 42.1% 
Hysterectomy 465 18.1% 930 24.9% 
Other days in hospital 51 2.0% 109 3.1% 
Total costs 2572 100.0% 3727 100.0% 
Of which: 
Costs for procedures 1649 64.1% 1634 43.8% 
Costs of hospitalisation$ 923 35.9% 2093 56.2% 
*Only consultations without colposcopy are charged; t One “primary colposcopy”, all others “secondary 
colposcopy” (see Table 2); SDfl494 per day in hospital. 
Table 4. Sensitivity analysis on average medical practice 
Number of 
women in Total costs 
Assumptions Colposcopies Consultations follow-up (MI-N) 
Baseline assumptions 35 977 56467 31559 21.5 
Initial management ofwomen with CIN I and CIN II 
Immediate treatment in all caries -14% -9% -7% -4.2% 
Initial cyto-kolposcopic follow-up in all cases* +19% + 12% +9% +5.6% 
Follow-up schedule after treatment 
1 year, colposcopy -38% -48% -65% -13% 
5 years, colposcopy during the whole period +95% + 24% +22% +20% 
*In which we assume that 50% of the followed-up women are treated eventually because regression isnot observed within 2 years. 
Percentage changes in annual t.otal number of colposcopies, consultations, length of follow-up period and costs of the management of screen- 
detected CIN in The Netherlands (calculations for 1990). 
total number of colposcopies (27 200) (see Table 1) which seems 
to be (80%) too high compared with the annual number of 15 466 
estimated from the data from the gynaecology department. This 
could partly be due to the cervical cancer screening programme 
reintroduced in The Netherlands since 1987. The total number 
of smears in 1988 was 20% higher than in 1987 [S]. A substantial 
number of the colposcopies induced by screening in 1988 will 
only be incorporated in later years and are not present in 
the reports of 1988. Moreover, the gynaecologists interviewed 
suggested that there had been substantial underregistration of 
colposcopies in their departments. 
As can be seen from Table 4, the length of the follow-up 
period after treatment is important both for the extent of the 
management for the women involved and for the costs. It also 
affects the number of colposcopies, which is important in 
terms of the capacity of the gynaecology departments. The 
considerable variety in practice shows the need for more evidence 
on how long a woman treated for CIN should be followed- 
up colposcopically. How much information colposcopy after 
treatment adds to cytology is questionable [PI. When only 
cytology is required, the women can be referred to the general 
practitioner. 
Other important cost factors are the number of women with 
CIN having conisation and hysterectomy, respectively. For the 
Dutch situation, we found that the number of hysterectomies in 
women with CIN III differs considerably (from 10% to almost 
50%) between hospitals [lo]. The use of hysterectomy for the 
treatment of CIN has been decreasing over recent decades. In a 
literature search for data from 1980 onwards we found three 
studies from British hospitals, in which 15-W% of the women 
with CIN had conk&ion and l-7% hysterectomy [l-3]. This 
compares favourably with the 41% and 8%, respectively, 
(retreatments included) recorded in this study. Each of these 
studies, however, came from one treatment centre, and quality 
bias (towards more conservative treatment) cannot be ruled out 
in data from publishing (= selected) centres. Our estimates on 
the use of conisation and hysterectomy are based on national 
data. Furthermore, in two of the studies from the United 
Kingdom [ 1, 21 conservative treatment was performed as an in- 
hospital treatment and under general anaesthesia. Conservative 
treatment in The Netherlands is performed as an out-patient 
treatment, under local (if any) anaesthesia. 
Current Dutch data, only the distribution of the conisations 
(and hysterectomies) over the different grades of CIN was based 
on less complete data (although coverage was much higher than 
in one-centre studies). The responding 10% of the gynaecology 
departments represent he larger hospitals, possibly causing an 
overestimation of the use of conservative treatment in CIN III. 
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Correction of such an overestimation i  our assessment would 
shift part of the conisations and hysterectomies from women 
with CIN I or II to women with CIN III, without affecting the 
total number of these treatment modalities used. 
Data from Loixxi and associates [Ill, also obtained from one 
treatment centre, show 73% conisations in women with CIN. 
Goodwin and colleagues [12], who performed a population- 
based study on all women from New Mexico with diagnosed 
carcinoma in situ of the cervix in 1982-1985, found 44% hyster- 
ectomies. (In The Netherlands, 40% of the CIN III diagnosis 
concerns carcinoma in situ.) These figures reflect more aggressive 
treatment strategies and probably large differences in gynaeco- 
logical practice between regions or countries. 
In The Netherlands, a conisation on average takes 4.5 days in 
hospital. If we hypothetically assume only one hospital day per 
conisation, this would reduce the total number of hospital days 
by 29%, and the total costs for the management of screen- 
detected CIN by 14% (calculations for 1990). As far as the cost 
per hospital day is concerned, women hospitalised for the 
treatment of CIN are probably more healthy than the average 
hospital population, and consequently, even having general 
anaesthesia, they might need less general care. If we arbitrarily 
decrease the cost per hospital day from Df1494 to DA 400, the 
total costs of the management of CIN would decrease by 9%. 
The evidence as to whether women with CIN I and II should 
be followed-up initially, to give regression a chance, or should 
be treated immediately, is inconclusive. Immediate treatment is 
less costly than the “wait and see” management, but the differ- 
ence is rather small (see Table 4). Treatment without delay saves 
2 years of follow-up maximum, at the expense of treating more 
women. The difference in the psychological burden to the 
women involved might be important, but this has hardly been 
quantified: on the one hand, anxiety may occur as long as no 
treatment has been given, on the other hand women in whom 
CIN regresses have the psychological advantage of not needing 
treatment for a condition associated with cancer. The gynaecolo- 
gist’s counselling strategy and attitude probably plays a major 
role in these psychological effects. 
Total costs for the management of woman with detected CIN 
amounted to 21.5 million guilders in The Netherlands in 1990 
(Table 4). This is almost as much as the sum of the assessed costs 
for the diagnosis and primary treatment of women with invasive 
cervical cancer (757 women in 1990, Nutionul Cancer 
Registration) of 14 million, and for advanced isease (288 women 
died from cervical cancer in 1990, Central Bureau of Statistics) of 
9 million [13]. 
In conclusion, the extent of the overall management of CIN is 
greater and the costs higher than might be expected. Although 
there has been a trend towards more conservative treatment, in 
The Netherlands half of the cases are treated with conisation or 
hysterectomy. The costs are substantial and the effect on the 
well-being of the women may be considerable. It is this overall 
practice that should be accounted for when balancing the 
benefits, unfavourable ffects and costs of cervical cancer screen- 
ing. A further trend towards less aggressive treatment in the near 
future from LEEP (Loop Electrosectional Excision Procedures) 
combined with “see and treat” strategies, and specific treatments 
for human oncogene, papillomavirus positive women, is contro- 
versial. Expectations will have to be reconciled not only with data 
from excellent treatment centres, but also with data reflecting 
overall practice. 
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